Daiwa Securities Group Inc. boosted its holdings in shares of Zoetis Inc (NYSE:ZTS) by 4.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,773 shares of the company’s stock after acquiring an additional 853 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Zoetis were worth $1,719,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Sun Life Financial INC boosted its position in shares of Zoetis by 604.3% during the second quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock worth $112,000 after buying an additional 1,124 shares during the period. Signature Estate & Investment Advisors LLC purchased a new position in shares of Zoetis during the third quarter worth $112,000. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Zoetis by 3,033.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after buying an additional 1,365 shares during the period. Fort L.P. purchased a new position in shares of Zoetis during the second quarter worth $121,000. Finally, Lenox Wealth Advisors LLC boosted its position in shares of Zoetis by 259.4% during the second quarter. Lenox Wealth Advisors LLC now owns 1,682 shares of the company’s stock worth $143,000 after buying an additional 1,214 shares during the period. 89.68% of the stock is owned by institutional investors.

Several research firms have recently commented on ZTS. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research report on Wednesday, October 17th. BMO Capital Markets restated a “hold” rating and set a $82.00 price target on shares of Zoetis in a research report on Thursday, August 2nd. Cantor Fitzgerald set a $98.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a research report on Tuesday, August 21st. They noted that the move was a valuation call. Finally, Argus raised their price target on Zoetis from $90.00 to $103.00 and gave the stock a “buy” rating in a research report on Tuesday, August 14th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and an average price target of $93.19.

In related news, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction on Monday, October 1st. The stock was sold at an average price of $92.03, for a total value of $184,060.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Juan Ramon Alaix sold 150,306 shares of Zoetis stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $94.96, for a total value of $14,273,057.76. Following the completion of the transaction, the chief executive officer now owns 246,319 shares of the company’s stock, valued at $23,390,452.24. The disclosure for this sale can be found here. Over the last quarter, insiders sold 350,507 shares of company stock valued at $32,579,830. 0.35% of the stock is currently owned by company insiders.

NYSE:ZTS opened at $95.27 on Friday. The firm has a market capitalization of $45.73 billion, a P/E ratio of 39.70, a P/E/G ratio of 1.87 and a beta of 0.97. Zoetis Inc has a 12-month low of $68.56 and a 12-month high of $96.57. The company has a quick ratio of 2.63, a current ratio of 4.06 and a debt-to-equity ratio of 3.04.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.06. The firm had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.46 billion. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. Zoetis’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business posted $0.65 earnings per share. Equities research analysts predict that Zoetis Inc will post 3.11 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Tuesday, November 20th will be issued a $0.126 dividend. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.53%. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.

TRADEMARK VIOLATION WARNING: This piece was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://theolympiareport.com/2018/11/11/zoetis-inc-zts-holdings-raised-by-daiwa-securities-group-inc.html.

Zoetis Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Read More: What are the most popular ETFs

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.